Wave Life Sciences Ltd. — Director's Dealing 2021

Feb 19, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Wave Life Sciences Ltd. (WVE)
CIK: 0001631574
Period of Report: 2021-02-01

Reporting Person: Francis Chris (See Remarks)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-01	Ordinary Shares	A	50000	$0.00	Acquired	81160	Direct
2021-02-16	Ordinary Shares	S	2698	$10.57	Disposed	78462	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-01	Share Option (right to buy)	$10.48	A	50000	Acquired	2031-02-01	Ordinary Shares (50000)	Direct

Footnotes

F1: Consists of restricted share units (RSUs). The RSUs vest in two equal installments on February 15, 2022 and February 15, 2023.

F2: On February 16, 2021, the reporting person sold 2,698 ordinary shares solely to cover taxes associated with the vesting of RSUs on February 15, 2021. These sales were made pursuant to a 10b5-1 Trading Plan.

F3: The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $10.51 to $10.58 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.

F4: The option vests as to 50% of the shares on February 15, 2022 and 50% on February 15, 2023.